Responding to Global Stimulant Use: Challenges and Opportunities

Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., ... & Shoptaw, S. (2019). Responding to global stimulant use: challenges and opportunities. The Lancet.
Publication Date

Stimulants drugs increase the activity of the central nervous system producing feelings of euphoria, increased confidence, sociability, energy, and wakefulness. 

Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder — A Systematic Review and Meta-Analysis

Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019). Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder–A Systematic Review and Meta‐analysis. Addiction.
Publication Date

This meta-analysis of research on medication to treat methamphetamine use disorder finds that only one medication, methylphenidate, has any efficacy in reducing use. 

Workplace Alcohol and Other Drug Factsheets

Created by
The National Centre for Education and Training on Addiction

To assist workplaces to respond to alcohol and other drug-related harm in the workplace, The National Centre for Education and Training on Addiction, has produced a series of factsheets about commonly used drugs and their impact on safety and well-being of individual employees, and overall safety and productivity of the workplace. 

Fact sheets cover the following topics:

Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States

Winkelman TNA, Admon LK, Jennings L, Shippee ND, Richardson CR, Bart G. Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States. JAMA Netw Open. 2018;1(6):e183758. doi:10.1001/jamanetworkopen.2018.3758
Publication Date

Key Points

Question: What are the current trends in frequency and costs of amphetamine-related hospitalizations in the United States?

Global Statistics on Alcohol, Tobacco and Illicit Drug Use: 2017 Status Report

Peacock, A., Leung, J., Larney, S., Colledge, S., Hickman, M., Rehm, J., Giovino, G. A., West, R., Hall, W., Griffiths, P., Ali, R., Gowing, L., Marsden, J., Ferrari, A. J., Grebely, J., Farrell, M., and Degenhardt, L. (2018) Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, doi: 10.1111/add.14234.
Publication Date



This review provides an up‐to‐date curated source of information on alcohol, tobacco and illicit drug use and their associated mortality and burden of disease. Limitations in the data are also discussed, including how these can be addressed in the future.

How Can Contingency Management Support Treatment for Substance Use Disorders? A Systematic Review

Published by
European Monitoring Centre for Drugs and Drug Addiction
Publication Date

Rewarding people dependent on illegal drugs for not using those drugs is a controversial tactic, one this report from the European Union’s drug misuse centre found patchily effective in extending retention and reducing substance use as a supplement to medication-based treatments. Read the Effectiveness Bank analysis.

Rise in Glutamate Levels Can Be Used to Predict Drug High

A study funded by the National Institute on Drug Abuse (NIDA) explores the action of psychostimulant drugs on glutamate, one of the most abundant neurotransmitters in the human body. Drugs with a stimulant effect are commonly prescribed to aid attention, energy and mood but will also often be abused "off-prescription" or prescribed medications misused. Researchers sought to better understand the effects of amphetamine and methamphetamine on glutamate and a range of neurometabolites. Two FDA approved

Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health

Weinstein AM, Rosca P, Fattore L and London ED (2017) Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health. Front. Psychiatry 8:156. doi: 10.3389/fpsyt.2017.00156
Publication Date

As part of an increasing worldwide use of designer drugs, recent use of compounds containing cathinones and synthetic cannabinoids is especially prevalent. Here, we reviewed current literature on the prevalence, epidemiology, bio-behavioral effects, and detection of these compounds. Gender differences and clinical effects will also be examined.